title: Nuclear assembly as a target for anti-cancer therapies.
abstract: Current anti-cancer therapies have a great deal of undesirable side effects; therefore, there is a need to develop efficient and cancer cell-specific new drugs without strong dose-limiting side effects. In my opinion, mechanisms of nuclear assembly and organization represent a novel platform for drug targets, which might fulfill these criteria. The nuclear stiffness and organization of some cancer types are often compromised, making them more vulnerable for further targeting the mechanisms of nuclear integrity than their normal counterparts. Here I will discuss the nuclear organization of normal cells and cancer cells, the molecular mechanisms that govern nuclear assembly with emphasis on those that, in my view, might be considered as targets for future anti-cancer therapies.
authors.affiliation: Bayer Pharma AG; Bayer Healthcare Pharmaceuticals; Global Drug Discovery; Therapeutic Research Group Oncology; Berlin, Germany.
authors.forename: Mátyás
authors.initials: M
authors.lastname: Gorjánácz
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D045744:Cell Line, Tumor; D016503:Drug Delivery Systems; D018390:Gene Targeting; D006801:Humans; D008938:Mitosis; D009369:Neoplasms / Q000235:genetics / Q000628:therapy*; D009687:Nuclear Proteins / Q000737:chemistry / Q000235:genetics*; D023041:Xenograft Model Antitumor Assays / Q000379:methods
chemical_list: D000970:Antineoplastic Agents; D009687:Nuclear Proteins
keywords: anti-mitotics; barrier-to-autointegration factor; cancer; cell cycle; drug discovery; nuclear envelope; nuclear organization; nucleus; vaccinia-related kinase